InvestorsHub Logo
Followers 44
Posts 4950
Boards Moderated 0
Alias Born 04/30/2005

Re: Doc328 post# 410825

Thursday, 04/13/2023 5:15:13 PM

Thursday, April 13, 2023 5:15:13 PM

Post# of 469991
Yes. After hiring Dr. Kun Jin, I think Anavex has the expertise to speed things up...so I don't think the SH meeting on May 23rd is out of the question.

Dr. Jin will draw on his extensive experience, including recently as the Statistical Team Leader at the U.S. Food and Drug Administration (FDA). Dr. Jin provided statistical review coverage and expertise for neurological drug products for the Center for Drug Evaluation and Research (CDER), and performed timely and quality reviews of marketing applications, including New Drug Applications (NDA), Biologic License Applications (BLA), and Investigational New Drug (IND) applications. Under the leadership of Dr. Jin, the neuropharmacological statistical team has completed several hundred statistical reviews of NDAs, BLAs, and efficacy supplements.


https://www.anavex.com/post/anavex-life-sciences-appoints-former-fda-lead-neurology-statistician-as-vp-head-of-biostatistics
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News